Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control

D. J. Christopher, V. Radha (Vellore, Tamilnadu, India)

Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Session: Recent advances in the treatment and pathogenesis of asthma
Session type: Thematic Poster Session
Number: 3630
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. J. Christopher, V. Radha (Vellore, Tamilnadu, India). Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control. Eur Respir J 2008; 32: Suppl. 52, 3630

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 209s
Year: 2006

In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Asthma control with a breath-actuated pressurised metered dose inhaler (BAI) and prevalence of oral candidiasis: a prescribing claims study of 1701 patients prescribed a traditional pressurised metered dose inhaler (MDI) plus spacer or a BAI
Source: Eur Respir J 2002; 20: Suppl. 38, 78s
Year: 2002

Assessment of the suitability of filters for use in clinical studies with an HFA fluticasone propionate pressurized metered dose inhaler (pMDI) and a valved holding chamber (VHC)
Source: Annual Congress 2011 - Lung function today and tomorrow II
Year: 2011

Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010


In vitro comparison of aerosol characteristics of HFA ipratropium bromide pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study.
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020


Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Technique training doesn‘t improve patients ability to use pressurised metered dose inhalers (pMDIs)
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009


Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 69s
Year: 2001

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017


Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients
Source: International Congress 2016 – Asthma management
Year: 2016


Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013